Ophthalmic Special Order Products, General Principles

Similar documents
Ophthalmic Special Order Products, General Principles

A Compendium of Product information & Indicative manufacturer s prices

Developed by Ipswich Hospital NHS Trust and Ipswich and East Suffolk Clinical Commissioning Group. Joint formulary - Ophthalmology

11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products

11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products

BNF CHAPTER 11: EYE 1 January 2018

11 Eye. To be used in conjunction with NICE guidance/guidelines, the British National Formulary for adults and/or children, and

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

Dry Eye Prescribing Guidelines

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta369

REFERENCE GUIDE FOR OPHTHALMIC PREPARATIONS AVAILABLE FOR USE BY ALL OPTOMETRISTS*

Medicines Q&As Q&A What are the therapeutic options for patients unable to take solid oral dosage forms?

South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway

Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

CICLOSPORIN EYE PREPERATIONS FACT SHEET TREATMENT OF OCULAR INFLAMMATORY CONDITIONS

Dry Eye Syndrome Prescribing Guidelines

GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY

NEW ZEALAND DATA SHEET 1. PRODUCT NAME

10 Musculoskeletal and Joint Diseases

AUSTRALIAN PRODUCT INFORMATION FLAREX (FLUOROMETHOLONE ACETATE) EYE DROPS SUSPENSION

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Dr.Sushil Kumar Tripathi

WELCOME. To learn more or place an order, please call

Quality, Safety and Sourcing in Unlicensed Medicines

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

MELATONIN Insomnia and Sleep Disorders in Children

How is the introduction of a new medicine regulated in the UK?

INDICATIONS For steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye globe.

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS

OPHTHALMIC GENERIC FORMULATIONS BY ADREA R. BENKOFF, M.D.

Proposed PIL NL/H/0653/001/IB/024/G. MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution in single-dose container Dexamethasone phosphate

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone

CYSTARAN (cysteamine hydrochloride) ophthalmic solution

Innovation In Ophthalmics

12.1 DRUGS ACTING ON THE EAR

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

Electronic Prescription Service (EPS) dm+d and Prescribing Systems

Scottish Dry Eye Guidelines

Conjunctivitis in Cats


Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

MAXIDEX Eye Drops 0.1%

MAXITROL* Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Ointment, USP 3.5 mg (as neomycin sulfate), 6000 IU/g, 0.

Allergies Formulary. Self Care

New Medicines Committee Briefing July Minims Povidone Iodine 5% w/v Eye Drops, Solution

Martindale Pharma is a UK pharmaceutical manufacturing company supplying niche products to over 50 countries worldwide.

Dry Eye Prescribing Guidelines

CLINICAL OPHTHALMIC THERAPEUTIC PHARMACEUTICAL AGENTS (TPA) QUICK REFERENCE GUIDE

Costing statement. Implementing NICE guidance. January NICE clinical guideline 137

New Zealand Data Sheet

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Student Practical Guide (1) Milk of Magnesia

Volume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN

OPTOMETRISTS REGULATION 33/2009

CILOXAN TM Eye Drops 0.3%

New Zealand Data Sheet

INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, for topical ophthalmic use Initial U.S. Approval: 1998

2019 Catalog Hospital and Ophthalmology Products and Services

ANNEX: Excipients and Information for the Package Leaflet

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Zatamil Mometasone furoate 0.1% w/w

Medication and Dysphagia To crush or not to crush? Paresh Parmar Care of Elderly & Stroke Pharmacist Northwick Park Hospital

Medicines Optimisation Strategy

1g cream or ointment contains 1 mg methylprednisolone aceponate.

Medicines Q&As Q&A Which medicines should be considered for brand-name prescribing in primary care?

Re-submission. Scottish Medicines Consortium. Olopatadine 1mg/ml eye drops, solution (Opatanol ) No. 59/03) Alcon Laboratories (UK) Ltd

SUBMISSION FOR RECLASSIFICATION OF MEDICINE. ZADITEN (KETOTIFEN 0.025% for Ophthalmic Use) TT , TT /1

MECS and Prescribing. Jane Bell BSc FCOptom, DipTpIP, Dip Glauc

MELATONIN Information for Primary Care

TA Number. TA Link. Annotation

Package Leaflet - Information for the User. TOBRADEX 3 mg/ml/1 mg/ml Eye Drops, Suspension Tobramycin and Dexamethasone

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

Package leaflet: Information for the user Oftaquix 5 mg/ml eye drops, solution. Levofloxacin

LYSOBACT COMPLETE SPRAY ( ) mg / ml Oromucosal spray, solution

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children

Drugs That May Be Used by Certain Optometrists

The Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.

nepafenac 1mg/mL eye drops, suspension (Nevanac ) SMC No. (813/12) Alcon Laboratories (UK) Ltd

July Formulary Policy

Pharmaceutical System in the UK

PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone

NEW ZEALAND DATA SHEET

Optometric Learning Network in Greater Glasgow & Clyde

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

Dr Rachael Neiderer. Ophthalmologist Auckland. 8:35-8:50 Managing Allergic Conjunctivitis & Why Sodium Chromoglycate is Out

Calgary Long Term Care Formulary

Chapter 12 Ear, Nose and Oropharynx

Release of the 2017/18 Invitation to Tender

Maxidex Eye Drops contain 1 mg/ml dexamethasone and is preserved with benzalkonium chloride (0.1 mg/ml).

Chemical Names: Prednisolone acetate: 11ß,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate.

Transcription:

Ophthalmic Special Order Products, General Principles When clinically appropriate and available, licensed products should always be prescribed and dispensed in preference to unlicensed products. Where a licensed product is not available, standard Drug Tariff products are preferred e.g. hypromellose 0.3%w/v or 0.5%w/v rather than 0.25%w/v Where a preservative-free (PF) preparation is clinically necessary, licensed Single Dose Units (SDUs) or licensed devices e.g. Tear-Lac should be prescribed if available Excipient intolerances should be included on the prescription (some licensed and unlicensed products including those labelled preservative-free contain potentially sensitising excipients) Preservative-free preparations should only be used for a limited period once opened. Justified and validated in-use shelf lives should be provided by the manufacturer. Single dose units should be used once only in accordance with the licence For items not on the list, please confirm with secondary care to ensure that a transcription error has not occurred. May 2014 2014/PROF/280 1

BNF name and form Anti-infectives G.Amphotericin 0.15%w/v PF G.Cefuroxime 5%w/v and PF (other strengths may be specified) G.Ciprofloxacin 0.2%w/v PF G.Gentamicin 1.5%w/v and PF (other strengths may be specified) G.Polihexanide 0.02%w/v G.Trifluorothymidine (Trifluridine) 1%w/v and PF Not suitable for primary care. 24 hr in-use shelf life as cannot be refrigerated. Licensed ciprofloxacin 0.3%w/w ointment (Ciloxan ) or licensed levofloxacin preservative-free (Oftaquix ) are preservative free alternatives. where applicable May 2014 2014/PROF/280 2

BNF name and form Lubricants and ciclosporin G.Acetylcysteine 0.5%w/v G.Acetylcysteine 5%w/v PF G.Acetylcysteine 10%w/v preserved and PF Oc.Ciclosporin 2%w/w Oc.Ciclosporin 0.2%w/w G.Ciclosporin 0.05%w/v PF SDUs G.Ciclosporin 0.06%w/v PF Suggest error, check if 5%w/v intended (Ilube ) For dry eye with mucous tear film in patients intolerant of benzalkonium chloride. (Ilube available which is not preservative free). If PF required confirmed, unlicensed special listed in Drug Tariff (not Northern Ireland).Fixed price to NHS. For severe dry eye with mucous tear film. Unlicensed special listed in Drug Tariff (not Northern Ireland or Scotland). Fixed price to NHS Suggest error, check if 0.2%w/w intended For severe dry eye, graft rejection, severe vernal conjunctivitis, some immune mediated disorders. Preservative-free but contains lanolin. Commercially available as veterinary product Optimmune Source from veterinary wholesaler*. Unlicensed special listed in Drug Tariff (not Northern Ireland or Scotland). Fixed price to NHS Available as licensed product in USA, Restasis. Licensed in USA as a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. May be imported as ophthalmic special order product. For severe dry eye, graft rejection, severe vernal conjunctivitis, some immune mediated disorders. Unlicensed product available in UK as alternative to 0.05%w/v. where applicable 37.53/ 57.33 per 10ml 46.88 per 10ml 80.98 per 3.5g 7.09 per 0.4ml May 2014 2014/PROF/280 3

BNF name and form G.Ciclosporin 2% PF G.Hypromellose 0.1%w/v PF G.Hypromellose 0.25%w/v G.Hypromellose 0.25%w/v preservative free G.Hypromellose 0.3%w/v PF G.Hypromellose 0.32%w/v PF, 0.5%w/v PF, 1%w/v PF G.Liquid Paraffin Light, G.Liquid Paraffin G.Sodium chloride 0.9%w/v PF Formulated in arachis oil therefore may be allocated 28 day in-use shelf life. Avoid in peanut allergy. Unlicensed special listed in Drug Tariff (not Northern Ireland or Scotland). Fixed price to NHS. Preserved - No advantage prescribing strengths other than licensed 0.3%w/v, Unlicensed special listed in Drug Tariff (not Northern Ireland).Fixed price to NHS. Preservative-free - Licensed preservative free single dose units classed as medicines e.g. Artelac 0.32%w/v and medical devices containing hypromellose 0.3%w/v e.g. Hydromoor 0.3%w/v, Lumecare 0.3%w/v and Tear-lac. Suggest Simple eye ointment, Lacrilube, Xailin Night or Vita-POS Other lubricants may be more suitable but if required, suggest Minims Saline where applicable 111.77 per 10ml 13.44/ 41.83 per 10ml 13.44 per 10ml May 2014 2014/PROF/280 4

Glaucoma BNF name and form Acetazolamide oral liquid Suggest rationalise strength to most frequently prescribed = 50mg/ml (250mg in 5ml) G.Glycerol 1%v/v and 10%v/v G.Pilocarpine 0.1%w/v, 0.25%w/v, 0.5%w/v G.Pilocarpine 0.4%w/v G.Pilocarpine 1-4%w/v PF G.Pilocarpine 6%w/v, 8%w/v Tablets will disperse in water. Use solution (not suspension) for fine bore naso-gastric tubes where there is a potential problem of blocking. For small doses e.g. 50mg, suspensions may be used administered using an oral syringe. includes the following formulations: standard formulation including standard flavours; sugar free; alcohol free; colour free; flavour free; lactose free and non-standard flavours 0.1%w/v normally used for diagnosis only. These strengths unlikely to be of benefit query strength. Suggest error, check is 4%w/v intended? Minims 2%w/v available if appropriate (no potentially sensitising excipients) or ask ophthalmologist to review. Very high strengths - check with prescriber where applicable Acetazolamide 250mg/5ml oral suspension 225.97 per 100ml May 2014 2014/PROF/280 5

BNF name and form Corticosteroids where applicable G.Dexamethasone 1%w/v G.Dexamethasone 0.1%w/v PF G.Prednisolone 0.003%w/v, 0.005%w/v 0.01%w/v G.Prednisolone 0.1%w/v preserved and PF G.Prednisolone 0.03%w/v, 0.05%w/v, 0.125%w/v preserved and preservativefree G.Prednisolone 0.25%w/v, 0.3%w/v, 0.5%w/v PF G.Prednisolone 0.3%w/v G.Prednisolone 1%w/v PF Suggest error, check is 0.1%w/v intended? Offer licensed single dose units of Dexamethasone Sodium Phosphate 0.1%w/v as alternative (Dropodex or Minims ). Exception could be patient who cannot tolerate phosphate or disodium edetate in licensed products. Unlicensed special listed at set price in Drug Tariff (not Northern Ireland or Scotland). Unlikely to be of benefit, query strength and see alternative strengths below Preferred strength for patients who require low strength topical corticosteroid. Unlicensed special listed at set price in Drug Tariff (not Northern Ireland), Only PF listed in Scotland. Suggest source 0.1%w/v from competitive manufacturer. Suggest licensed Minims Prednisolone Sodium Phosphate 0.5%w/v as alternative. 0.3%w/v unlicensed special listed at set price in Drug Tariff (not Northern Ireland or Scotland). Suggest licensed 0.5%w/v (Predsol ) or if not available, betamethasone 0.1%w/v (Betnesol, Vista-methasone ), fluoromethalone (FML ), loteprednol (Lotemax ), rimexolone (Vexol ) or Minims Prednisolone Sodium Phosphate 0.5%w/v. Unlicensed special listed at set price in Drug Tariff (not Northern Ireland), Only PF listed in Scotland. This product would be the prednisolone sodium phosphate so not equivalent potency to prednisolone acetate 1%w/v (PredForte ), ascertain prescriber is aware. Offer Minims Prednisolone Sodium Phosphate 0.5%w/v, Dropodex or Minims Dexamethasone sodium Phosphate 0.1%w/v as alternative. If required source from competitive manufacturer. 24.64 per 10ml 28.88 per 10ml 28.88/ 53.30 per 10ml 0.03%w/v 29.32 per 10ml 0.3%w/v 29.16 per 10ml 31.73 per 10ml May 2014 2014/PROF/280 6

Ophthalmic Special Miscellaneous G.Cysteamine/ Mercaptamine eye drops 0.11%w/v G.Cysteamine/ Mercaptamine eye drops 0.44%w/v G.Cysteamine/ Mercaptamine eye drops 0.55%w/v G.Sodium chloride 0.5%w/v and 0.45%w/v Oc.Sodium chloride 5%w/w G.Sodium chloride PF 5%w/v G.Sodium chloride 5%w/v (Scotland) G.Sodium citrate 10.11%w/v G.Sodium cromoglicate 2%w/v PF For cystinosis. 0.55%w/v is more frequently used. Single source amongst NHS manufacturing units. May be imported as ophthalmic special order product. Available as licensed product in USA, Cystaran. CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. For cystinosis. Single source amongst NHS manufacturing units. Likely to be an error check if 5%w/v or 4.5%w/v - if 4.5%w/v, suggest 5%w/v For corneal oedema, recurrent corneal erosion syndrome. Preserved with methyl parahydroxybenzoate and propyl parahydroxybenzoate also contains lanolin. Unlicensed special listed in Drug Tariff (not Northern Ireland or Scotland). Fixed price to NHS For corneal oedema, recurrent corneal erosion syndrome. Alternatives are eye ointment (see above), prescribable PF single dose units ( 73.58 for 20 x 0.45ml single dose units, licensed medical device available in England, Wales and Northern Ireland) or benzalkonium chloride-free sodium chloride 5%w/v eye drops (licensed medical device available in England, Wales and Northern Ireland see below) which may be acceptable. If unacceptable, unlicensed special listed in Drug Tariff (not Northern Ireland or Scotland). Fixed price to NHS For corneal oedema, recurrent corneal erosion syndrome. Unlicensed medicine in Scotland. Available as prescribable licensed medical device in England, Wales and Northern Ireland listed in Drug Tariff e.g. Hypersal at 25.25 per 10ml Suggest commercially available product Catacrom. No potentially sensitising excipients. May 2014 2014/PROF/280 7 Drug Tariff price England & where applicable 28.82 per 5g. 21.14 per 10ml. 25.25 per 10ml

Ophthalmic Special Mydriatics G.Atropine 1%w/v PF G.Homatropine hydrobromide 2%w/v PF G. = eye drops Oc. = eye ointment Minims Atropine Sulphate 1%w/v may be suitable alternative. No potentially sensitising excipients. Suggest alternative commercially available mydriatic-cycloplegic e.g. Minims Cyclopentolate Hydrochloride, Minims Tropicamide. No potentially sensitising excipients. Drug Tariff price England & where applicable Unlicensed specials listed in Drug Tariff for Wales in part VIIIB, for Scotland in part 7S. Eye drops classed as medical devices listed in Drug Tariff for Wales in part IXA, for Scotland in part 3, for Northern Ireland in part III. Special order manufacturers listed in the British National Formulary are preferred suppliers. Local ophthalmic unit in secondary care may advise. *Veterinary wholesalers will supply to community pharmacists. (Pharmacies dealing with veterinary products may not possess a Wholesale Dealer s licence and therefore only supply against prescriptions from veterinary prescribers). May 2014 2014/PROF/280 8